Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 486

1.

Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.

Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:260-6. doi: 10.1016/j.pnpbp.2012.10.010. Epub 2012 Oct 18.

PMID:
23085073
[PubMed - indexed for MEDLINE]
2.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

PMID:
15600384
[PubMed - indexed for MEDLINE]
3.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

PMID:
23218100
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
[PubMed - indexed for MEDLINE]
5.

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.

Psychopharmacology (Berl). 2006 Dec;189(2):259-66. Epub 2006 Oct 21.

PMID:
17058105
[PubMed - indexed for MEDLINE]
6.

The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.

Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R.

J Clin Psychiatry. 2009 Mar;70(3):318-25. Epub 2008 Dec 16.

PMID:
19192469
[PubMed - indexed for MEDLINE]
7.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

PMID:
21768610
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
[PubMed - indexed for MEDLINE]
9.

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM.

J Clin Psychopharmacol. 2009 Aug;29(4):362-7. doi: 10.1097/JCP.0b013e3181ac9b0b.

PMID:
19593176
[PubMed - indexed for MEDLINE]
10.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
[PubMed - indexed for MEDLINE]
11.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
[PubMed - indexed for MEDLINE]
12.

Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.

Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, McQuade RD, Crandall DT, Carson WH, Marcus RN, L'italien G.

Schizophr Res. 2008 Dec;106(2-3):300-7. doi: 10.1016/j.schres.2008.09.002. Epub 2008 Oct 29.

PMID:
18973991
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.

Lee SY, Park MH, Patkar AA, Pae CU.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):490-6. doi: 10.1016/j.pnpbp.2010.12.003. Epub 2010 Dec 10.

PMID:
21146575
[PubMed - indexed for MEDLINE]
14.

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.

Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH.

Biol Psychiatry. 2009 Mar 15;65(6):510-7. doi: 10.1016/j.biopsych.2008.07.033. Epub 2008 Nov 4.

PMID:
18986646
[PubMed - indexed for MEDLINE]
15.

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.

PMID:
19512978
[PubMed - indexed for MEDLINE]
16.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
[PubMed - indexed for MEDLINE]
17.

Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.

Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC.

Paediatr Drugs. 2013 Apr;15(2):139-50. doi: 10.1007/s40272-013-0016-6. Review.

PMID:
23519708
[PubMed - indexed for MEDLINE]
18.

Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.

McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP.

J Clin Psychiatry. 2005 Sep;66(9):1161-8.

PMID:
16187775
[PubMed - indexed for MEDLINE]
19.

Aripiprazole in schizophrenia and schizoaffective disorder: A review.

Stip E, Tourjman V.

Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021. Review.

PMID:
20152550
[PubMed - indexed for MEDLINE]
20.

Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.

L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN.

J Clin Psychiatry. 2007 Oct;68(10):1510-6.

PMID:
17960964
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk